Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Ovarian Neoplasms

Free Subscription Articles published in Obstet Gynecol Retrieve available abstracts of 44 articles: HTML format Text format

Single Articles

February 2020
1. BRISTOW RE, Chang J, Villanueva C, Ziogas A, et al
   A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.
   Obstet Gynecol. 2020 Feb 9. doi: 10.1097/AOG.0000000000003665.
   PubMed     Text format     Abstract available
   
   
   
2. BULL PHELPS SL, Jackson-Moore LA
   Ovarian Cancer Care in the Affordable Care Act Era: Ovarian Cancer Breaking the Silence?
   Obstet Gynecol. 2020 Feb 9. doi: 10.1097/AOG.0000000000003679.
   PubMed     Text format    
   
   
   
3. SMITH AJB, Fader AN
   Association of the Affordable Care Act With Ovarian Cancer Care.
   Obstet Gynecol. 2020 Feb 9. doi: 10.1097/AOG.0000000000003630.
   PubMed     Text format     Abstract available
   
   
   October 2019
4. MATSUO K, Machida H, Yamagami W, Ebina Y, et al
   Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer.
   Obstet Gynecol. 2019 Oct 8. doi: 10.1097/AOG.0000000000003507.
   PubMed     Text format     Abstract available
   
   
   September 2019
5. WHEELER LJ, Desanto K, Teal SB, Sheeder J, et al
   Intrauterine Device Use and Ovarian Cancer Risk: A Systematic Review and Meta-analysis.
   Obstet Gynecol. 2019 Sep 10. doi: 10.1097/AOG.0000000000003463.
   PubMed     Text format     Abstract available
   
   
   June 2019
6. WRIGHT JD, Huang Y, Melamed A, Tergas AI, et al
   Potential Consequences of Minimum-Volume Standards for Hospitals Treating Women With Ovarian Cancer.
   Obstet Gynecol. 2019;133:1109-1119.
   PubMed     Text format     Abstract available
   
   
   May 2019
7. WRIGHT JD, Huang Y, Melamed A, Tergas AI, et al
   Potential Consequences of Minimum-Volume Standards for Hospitals Treating Women With Ovarian Cancer.
   Obstet Gynecol. 2019 May 9. doi: 10.1097/AOG.0000000000003288.
   PubMed     Text format     Abstract available
   
   
   April 2019
8. 
   ACOG Committee Opinion No. 774: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention.
   Obstet Gynecol. 2019;133:e279-e284.
   PubMed     Text format     Abstract available
   
   
   
9. 
   ACOG Committee Opinion No. 774 Summary: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention.
   Obstet Gynecol. 2019;133:842-843.
   PubMed     Text format     Abstract available
   
   
   March 2019
10. DOTTINO JA, Moss HA, Lu KH, Secord AA, et al
    U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    Obstet Gynecol. 2019 Mar 11. doi: 10.1097/AOG.0000000000003171.
    PubMed     Text format     Abstract available
    
    
    January 2019
11. ROSE PG, Java JJ, Salani R, Geller MA, et al
    Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.
    Obstet Gynecol. 2019 Jan 8. doi: 10.1097/AOG.0000000000003086.
    PubMed     Text format     Abstract available
    
    
    November 2018
12. WRIGHT JD
    What Is New in Ovarian Cancer?: Best Articles From the Past Year.
    Obstet Gynecol. 2018 Nov 5. doi: 10.1097/AOG.0000000000002989.
    PubMed     Text format     Abstract available
    
    
    October 2018
13. VAN NAGELL JR JR, Burgess BT, Miller RW, Baldwin L, et al
    Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening.
    Obstet Gynecol. 2018 Oct 5. doi: 10.1097/AOG.0000000000002921.
    PubMed     Text format     Abstract available
    
    
    
14. ROBERTSON SE, Peipert JF
    Ultrasound Screening for Ovarian Cancer: Are We There Yet?
    Obstet Gynecol. 2018 Oct 5. doi: 10.1097/AOG.0000000000002962.
    PubMed     Text format    
    
    
    
15. SUH-BURGMANN E, Flanagan T, Osinski T, Alavi M, et al
    Prospective Validation of a Standardized Ultrasonography-Based Ovarian Cancer Risk Assessment System.
    Obstet Gynecol. 2018 Oct 5. doi: 10.1097/AOG.0000000000002939.
    PubMed     Text format     Abstract available
    
    
    August 2018
16. FLEMING ND, Nick AM, Coleman RL, Westin SN, et al
    Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.
    Obstet Gynecol. 2018 Aug 6. doi: 10.1097/AOG.0000000000002796.
    PubMed     Text format     Abstract available
    
    
    
17. FILIPPOVA OT, Chi DS
    The Unyielding Fight Against the Premature Death of Patients With Advanced-Stage Ovarian Cancer.
    Obstet Gynecol. 2018 Aug 6. doi: 10.1097/AOG.0000000000002883.
    PubMed     Text format    
    
    
    July 2018
18. GIRAUDET G, Rubod C, Collinet P, Cosson M, et al
    Salpingectomy During Vaginal Hysterectomy: A Surgical Technique to Make It Easier.
    Obstet Gynecol. 2018 Jul 10. doi: 10.1097/AOG.0000000000002746.
    PubMed     Text format     Abstract available
    
    
    June 2018
19. UPPAL S, Spencer RJ, Rice LW, Del Carmen MG, et al
    Hospital Readmission as a Poor Measure of Quality in Ovarian Cancer Surgery.
    Obstet Gynecol. 2018 Jun 6. doi: 10.1097/AOG.0000000000002693.
    PubMed     Text format     Abstract available
    
    
    May 2018
20. SAAVALAINEN L, Lassus H, But A, Tiitinen A, et al
    Risk of Gynecologic Cancer According to the Type of Endometriosis.
    Obstet Gynecol. 2018 May 7. doi: 10.1097/AOG.0000000000002624.
    PubMed     Text format     Abstract available
    
    
    April 2018
21. MENON U, Karpinskyj C, Gentry-Maharaj A
    Ovarian Cancer Prevention and Screening.
    Obstet Gynecol. 2018 Apr 6. doi: 10.1097/AOG.0000000000002580.
    PubMed     Text format     Abstract available
    
    
    
22. WALLACE SK, Halverson JW, Jankowski CJ, DeJong SR, et al
    Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy.
    Obstet Gynecol. 2018 Apr 6. doi: 10.1097/AOG.0000000000002463.
    PubMed     Text format     Abstract available
    
    
    November 2017
23. BERCOW AS, Chen L, Chatterjee S, Tergas AI, et al
    Cost of Care for the Initial Management of Ovarian Cancer.
    Obstet Gynecol. 2017 Nov 3. doi: 10.1097/AOG.0000000000002317.
    PubMed     Text format     Abstract available
    
    
    
24. PASCUAL MA, Graupera B, Pedrero C, Rodriguez I, et al
    Long-term Results for Expectant Management of Ultrasonographically Diagnosed Benign Ovarian Teratomas.
    Obstet Gynecol. 2017 Nov 3. doi: 10.1097/AOG.0000000000002327.
    PubMed     Text format     Abstract available
    
    
    October 2017
25. DILLEY SE, Straughn JM Jr, Leath CA 3rd
    The Evolution of and Evidence for Opportunistic Salpingectomy.
    Obstet Gynecol. 2017;130:814-824.
    PubMed     Text format     Abstract available
    
    
    September 2017
26. LIPPITT MH, Fairbairn MG, Matsuno R, Stone RL, et al
    Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer.
    Obstet Gynecol. 2017 Sep 5. doi: 10.1097/AOG.0000000000002213.
    PubMed     Text format     Abstract available
    
    
    
27. VISSER NCM, Reijnen C, Massuger LFAG, Nagtegaal ID, et al
    Accuracy of Endometrial Sampling in Endometrial Carcinoma: A Systematic Review and Meta-analysis.
    Obstet Gynecol. 2017 Sep 5. doi: 10.1097/AOG.0000000000002261.
    PubMed     Text format     Abstract available
    
    
    
28. 
    Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.
    Obstet Gynecol. 2017;130:e146-e149.
    PubMed     Text format     Abstract available
    
    
    
29. 
    Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
    Obstet Gynecol. 2017;130:e110-e126.
    PubMed     Text format     Abstract available
    
    
    
30. 
    Committee Opinion No. 716 Summary: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.
    Obstet Gynecol. 2017;130:664-665.
    PubMed     Text format     Abstract available
    
    
    
31. 
    Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.
    Obstet Gynecol. 2017;130:657-659.
    PubMed     Text format     Abstract available
    
    
    August 2017
32. WRIGHT JD, Chen L, Hou JY, Burke WM, et al
    Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer.
    Obstet Gynecol. 2017 Aug 4. doi: 10.1097/AOG.0000000000002164.
    PubMed     Text format     Abstract available
    
    
    
33. MARTINELLI F, Ditto A, Bogani G, Raspagliesi F, et al
    Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy.
    Obstet Gynecol. 2017;130:469-470.
    PubMed     Text format    
    
    
    July 2017
34. SPENCER RJ, Hacker KE, Griggs JJ, Rice LW, et al
    Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery.
    Obstet Gynecol. 2017 Jul 7. doi: 10.1097/AOG.0000000000002140.
    PubMed     Text format     Abstract available
    
    
    
35. MATSUO K, Machida H, Stone RL, Soliman PT, et al
    Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer.
    Obstet Gynecol. 2017 Jul 7. doi: 10.1097/AOG.0000000000002142.
    PubMed     Text format     Abstract available
    
    
    
36. CORY L, Latif N, Brensinger C, Zhang X, et al
    Readmission After Gynecologic Surgery: A Comparison of Procedures for Benign and Malignant Indications.
    Obstet Gynecol. 2017 Jul 7. doi: 10.1097/AOG.0000000000002141.
    PubMed     Text format     Abstract available
    
    
    June 2017
37. MELAMED A, Rizzo AE, Nitecki R, Gockley AA, et al
    All-Cause Mortality After Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer.
    Obstet Gynecol. 2017 Jun 6. doi: 10.1097/AOG.0000000000002102.
    PubMed     Text format     Abstract available
    
    
    May 2017
38. BAKKUM-GAMEZ JN, Dowdy SC
    Venous Thromboembolism: An Unrecognized Crisis in Gynecologic Oncology.
    Obstet Gynecol. 2017 May 8. doi: 10.1097/AOG.0000000000002073.
    PubMed     Text format    
    
    
    
39. GRECO PS, Bazzi AA, McLean K, Reynolds RK, et al
    Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy.
    Obstet Gynecol. 2017 May 5. doi: 10.1097/AOG.0000000000001980.
    PubMed     Text format     Abstract available
    
    
    
40. FAJAU-PREVOT C, Le Gac YT, Chevreau C, Cohade C, et al
    Ovarian Mucinous Cystadenoma After Ovarian Graft.
    Obstet Gynecol. 2017 May 5. doi: 10.1097/AOG.0000000000001990.
    PubMed     Text format     Abstract available
    
    
    April 2017
41. MELAMED A, Nitecki R, Boruta DM 2nd, Del Carmen MG, et al
    Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy.
    Obstet Gynecol. 2017 Apr 4. doi: 10.1097/AOG.0000000000001851.
    PubMed     Text format     Abstract available
    
    
    February 2017
42. GOCKLEY A, Melamed A, Bregar AJ, Clemmer JT, et al
    Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.
    Obstet Gynecol. 2017 Feb 6. doi: 10.1097/AOG.0000000000001867.
    PubMed     Text format     Abstract available
    
    
    September 2016
43. MATSUO K, Machida H, Shoupe D, Melamed A, et al
    Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
44. EVANS EC, Matteson KA, Orejuela FJ, Alperin M, et al
    Salpingo-oophorectomy at the Time of Benign Hysterectomy: A Systematic Review.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: